OncoMatch/Clinical Trials/NCT05717166
A Randomized Phase III Trial of Stereotactic Ablative Radiotherapy for Patients With Up to 10 Oligometastases and a Synchronous Primary Tumor.
Is NCT05717166 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Chemotherapy and Hormone therapy for metastatic tumor.
Treatment: Chemotherapy · Hormone therapy · Immunotherapy · Targeted Systemic Therapy — This study is a phase III multi-institutional randomized trial. Patients will be randomized in a 1:2 ratio between current standard of care treatment (Arm 1) vs. standard of care treatment + SABR (Arm 2) to sites of known disease. Patients will be stratified by two of the strongest prognostic factors, based on a large multi-institutional analysis3: histology (Group 1: hormone-sensitive prostate cancer, breast, or renal; Group 2: all others), and number of metastases (Group 1: 1-3; Group 2: 4-10).
Check if I qualifyExtracted eligibility criteria
Disease stage
Metastatic disease required
Performance status
KARNOFSKY 61–100
Karnofsky performance status > 60
Lab requirements
Liver function
For patients with liver metastases, moderate/severe liver dysfunction (Child Pugh B or C) excluded.
For patients with liver metastases, moderate/severe liver dysfunction (Child Pugh B or C); please see the Child-Pugh score calculator.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify